CardioGenesis to Participate in International Meeting of Society of Thoracic Surgeons
Thursday January 20, 7:30 am ET
Company Launching Advanced TMR PLUS Platform to Cardiothoracic Surgeons
FOOTHILL RANCH, Calif., Jan. 20 /PRNewswire-FirstCall/ -- CardioGenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC), today announced it will be exhibiting at the 41st annual meeting of The Society of Thoracic Surgeons (STS) held January 23 - 26 in Tampa. The Company will be formally launching its recently FDA approved advanced laser console for TMR, the SolarGen 2100s and their new celleratOR PRP system for point of care preparation of platelet rich plasma (PRP).
ADVERTISEMENT
Chairman and CEO, Michael J. Quinn commented, "These are the first new products we will be launching to our cardiothoracic customers in over two years. We have worked closely with leading innovative clinicians in developing our advanced TMR PLUS platform, including the recently FDA approved SolarGen laser system. We are excited to be formally launching it to the international audience that attends the STS." Quinn added, "We will also be introducing our celleratOR PRP system, providing the patient's own platelet concentration from a small centrifuge system. This product has achieved significant penetration in several other surgical specialties, and we are excited to be bringing it to the cardiovascular market."
The Company is supporting an educational symposium in conjunction with the STS Meeting. The presentations will include: Robotic and thoracoscopic minimally invasive TMR procedures; PRP in cardiac applications; and the FDA approved SynCardia CardioWest Temporary Artificial Heart (TAH-t) to be presented by Jack G. Copeland, MD of the University of Arizona Health Sciences Center. The symposium will be held in the Tampa Marriott Waterside Hotel, Meeting Room 6 with Dr. Copeland opening the program at 6:30 PM. For clinical attendees to the symposium, the Company will be providing the opportunity to win a scholarship in 2005 to the Course on Non-Sternotomy Cardiac Surgery with Randall K. Wolf, MD at the University of Cincinnati. The Company is supporting this advanced practice course, which includes training on thoracoscopic TMR.
"Having proven the significant and enduring benefits of TMR, we have focused on bringing advanced devices and tools to expand the eligible patient population. We are excited to be going into the STS, our biggest meeting of the year, with strong momentum from the end of 2004 and a series of new products to introduce at the meeting," explained Quinn. "We have an opportunity to drive revenue growth in 2005 with these new products, with more to follow soon."
About CardioGenesis Corporation
CardioGenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the CardioGenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
For more information on the Company and its products, please visit the CardioGenesis company web site at www.cardiogenesis.com or the patient and physician website at www.heartofnewlife.com. Heartofnewlife.com is a resource for patients and physicians which provides medical information on TMR.
With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause CardioGenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2003, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004, and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
For further information, please contact Michael J. Quinn, President and Chief Executive Officer, +1-714-649-5050, or Richard Lanigan, Senior VP, Marketing, +1-714-649-5024, both of CardioGenesis Corporation.
--------------------------------------------------------------------------------
